S-adenosylmethionine (SAMe) for depression

Psychiatric Annals

Volumn 32, Issue 1, 2002, Pages 29-44

  Brown, Richard P ^a   Gerbarg, Patricia ^c   Bottiglieri, Teodoro ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b BAYLOR UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; FENOTEROL; IMIPRAMINE; METHOTREXATE; MIANSERIN; MINAPRINE; NOMIFENSINE; PHENELZINE; PLACEBO; PSYCHOTROPIC AGENT; RESERPINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DNA METHYLATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG UPTAKE; ELECTROCONVULSIVE THERAPY; HEADACHE; HEART PALPITATION; HUMAN; HYPOTHERMIA; INSOMNIA; KIDNEY CLEARANCE; MANIA; NAUSEA; NERVOUSNESS; NEUROPHARMACOLOGY; NONHUMAN; PSYCHOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; SWIMMING; TERATOGENICITY; VERTIGO; XEROSTOMIA;

EID: 0036115957     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020101-07     Document Type: Review

References (100)

1. Stramentinoli G, Gualano M, Catto E, Algeri S. Tissue levels of S-adenosylmethionine in aging rats. Journal of Gerontology. 1977;32:392-394.
2. Cheng X, Blumenthal RM. S-Adenosylmethionine-Dependent Methyltransferase: Structures and Functions. Singapore: World Scientific Publishing; 1999.
3. Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. FASEB J. 1996;10:471-480.
4. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L- methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol. 1994;29:597-604.
5. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 1989;24:407-415.
6. Castagna A, Le Grazie C, Accordini A, et al. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: the effect of parenteral treatment with SAMe. Neurology. 1995;45:1678-1683.
7. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation: an in vitro study. Am J Med. 1987;83:48-54.
8. Konig H, Stahl H, Sieper J, Wolf KJ. Magnetic resonance tomography of finger polyarthritis: morphology and cartilage signals after ademetionine therapy. Actuelle Radiologie. 1995;5:36-40.
9. Zhang M, Borovikova LV, Wang H, Metz C, Tracey KJ. Spermine inhibition of monocyte activation and inflammation. Mol Med. 1999;5:595-605.
10. Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenan paw edemata: possible mecha nism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical. Agents and Actions. 1984;14:228-237.
11. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis: review of the clinical studies. Am J Med. 1987;83:60-65.
12. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096-1098.
13. Pall HS, Surtees R, Sturman SG. S-adenosylmethionine in cerebrospinal fluid in Parkinson's Disease (PD). Neurology. 1992;42:283. Abstract.
14. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders: clinical potential. Drugs. 1993;45:623-636.
15. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12 and homocysteine in major depressive disorders. Am J Psychiatry. 1997;154:426-428.
16. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60:121-130.
17. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol. 1997;145:580-585.
18. Carrieri PB, Indaco A, Gentile S. S-Adenosylmethionine treatment of depression in patients with Parkinson's disease: a double-blind crossover study versus placebo. Current Therapeutic Research. 1990;48:154-160.
19. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Journal of Movement Disorders. 2000;15:1225-1229.
20. Cergnul I, Jones K, Ernst D, Goldenberg R, Brown RP. S- adenosylmethionine in the treatment of depressive disorders in HIV-positive individuals: interim results. Presented at AmFAR 13th National HIV/AIDS Update Conference; March 20-23, 2001; San Francisco, CA. Abstract.
21. Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology. 1988;8:65-68.
22. Osman E, Owen JS, Burroughs AK. Review article: S-adenosyl-L-methionine: a new therapeutic agent in liver disease? Alimentary Pharmacology and Therapeutics. 1993;7:21-28.
23. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosyl-methionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-1089.
24. Benevenga NJ. Toxicities of methionine and other amino acids. J Agric Food Chem. 1974;22:2-9.
25. Merino GE, Jetzer T, Doizaki WM, Najarian JS. Methionine-induced hepatic coma in dogs. Am J Surg. 1975;130:41-46.
26. Hardwick DF, Applegarth DA, Cockcroff DM. Pathogenesis of methionine-induced toxicity. Metabolism. 1970;19:381-391.
27. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
28. Guthikonda S, Haynes WG. Homocysteine as a novel risk factor for atherosclerosis. Curr Opin Cardiol. 1999;14:283-291.
29. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-1779.
30. Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5- methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:727-733.
31. Loehrer FM, Schwab R, Angst CP, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther. 1997;282:845-850.
32. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev. 1996;54:382-390.
33. Giulidori P, Cortello M, Moreo G, Stramentinoli G. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. Eur J Clin Pharmacol. 1984;227:119-121.
34. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine: pharmacokinetics and pharmacodynamics. Am J Med. 1987;83:35-42.
35. Bottiglieri T, Chary TK, Laundy M, et al. Transmethylation and depression. The Alabama Journal of Medical Sciences. 1988;25:296-301.
36. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opinion on Investigational Drugs. 1997;6:417-426.
37. Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. Gen Pharmacol. 1989;20:403-406.
38. Curcio M, Catto E, Stramentinoli G, et al. Effect of S-adenosyl-L- methionine on serotonin metabolism in rat brain. Prog Neuropsychopharmacol. 1978;2:65-71.
39. Bottiglieri T, Carney MWP, Edeh J, et al. S-adenosylmethionine influences monoamine metabolism. Lancet. 1984;2:224. Letter.
40. Agnoli A, Ruggieri S, Cerone CG, et al. The dopamine hypothesis of depression: results of treatment with dopaminergic drugs. In: Grattini S, ed. Depressive Disorders. Stuttgart, Germany: FK Schatauer Verlag; 1977:447-458.
41. Mishima K, Higuchi H, Kamata M, et al. Effect of acute and chronic S-adenosylmethionine (SAM) administration on dopaminergic function in rat striatum. Proceedings of the Japanese Society of Biochemical Pharmacology. 1994;15:714.
42. Bottiglieri T, Hyland K. Effect of S-adenosylmethionine on dopamine metabolism in the rat striatum: an in-vivo microdialysis study. Soc Neurosci Abstracts. 1996;2:834.
43. Mann S, Hill MW. Activation and inactivation of striatal tyrosine hydroxylase: the effects of pH, ATP, and cyclic AMP, S-adenosylmethionine and S-adenosylhomocysteine. Biochemical Pharmacology. 1983;32:3369-3374.
44. Czyrak A, Rogoz Z, Skuza G, et al. Antidepressant activity of S-adenosyl-L-methionine in mice and rats. J Basic Clin Physiol Pharmacol. 1992;3:1-17.
45. Cohen B, Stramentinoli G, Sosa AL, et al. Effects of the novel antidepressant S-adenosylmethionine on alpha-1 and beta-adrenoreceptors in rat brain. Eur J Pharmacol. 1989;170:201-207.
46. Cimino M, Vantini G, Algeri S, Curatola G, Pezzoli C, Stramentinoli G. Age-related modification of dopaminergic and beta-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci. 1984;34:2029-2039.
47. Hirata F, Strittmatter WJ, Axelrod J. Beta-Adrenergic receptor agonists increase phospholipid methylation, membrane fluidity and beta-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sci U S A. 1979;76:368-372.
48. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R. Effect of S-adenosyl-L-methionine on brain muscarinic receptors. Eur J Pharmacol. 1992;227:293-299.
49. Pavia J, Martos F, Gonzalez-Correa JA, et al. Effect of S-adenosyl methionine on muscarinic receptors in young rats. Life Sci. 1997;60:825-832.
50. Bonanno G, Marchi M, Raiteri M. Activation of muscarinic receptors on striatal synaptosomes increases the release of endogenous dopamine. Neuropharmacology. 1985;24:261-264.
51. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. Journal of the American Chemical Society. 1952;74:2942-2943.
52. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R. Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes. Minerva Medica. 1973;64:1515-1529.
53. Janicak PG, Lipinski J, Davis J, et al. S-adenosylmethionine in depression: a literature review and preliminary report. The Alabama Journal of Medical Sciences. 1988;25:306-313.
54. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine: a review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs. 1989;38:389-416.
55. Bressa GM. S-adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;89(S154):7-14.
56. Criconia AM, Araquistain JM, Daffina N, et al. Results of treatment with S-adenosyl-L-methionine in patients with major depression and internal illnesses. Current Therapeutic Research. 1994;55:666-674.
57. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res. 1995;56:295-297.
58. Salvadorini F, Galeone F, Saba P, et al. Evaluation of S-adenosylmethionine (SAMe) effectiveness on depression. Current Therapeutic Research. 1980;27:908-918.
59. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res. 1976;13:43-54.
60. Carney MWP, Edeh J, Bottiglieri T, et al. Affective illness and S-Adenosyl Methionine: a preliminary report. Clin Neuropharmacol. 1986;9:379-385.
61. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990;147:591-595.
62. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59:34-40.
63. Cerutti R, Sichel MP, Perin M, et al. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. Current Therapeutic Research. 1993;53:707-716.
64. Delle Chiale R, Boissard G. Presented at the World Biological Psychiatry Congress (90-56). Biol Psychiatry. 1997;42:245S. Abstract.
65. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand. 1992;86:42-45.
66. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Current Therapeutic Research. 1992;52:478-485.
67. Scarzella R, Appiotti A. Confronto clinico in doppio cieco della SAMe versus chlomiprimina nelle sindromi depressive. Rivista Sperimentale di Feniatra. 1978;102:359-365.
68. Delle Chiale R, Panccheri P, Scapicchio P. MC3: multicenter controlled efficacy and safety trial of oral S-adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. Presented at Collegium Internationale Neuro-Psychopharmacologisum (CINP); July 9-13, 2000; Brussels, Belgium.
69. Delle Chiale R, Panccheri P, Scapicchio P. MC4: multicenter controlled efficacy and safety trial of intramuscular S-adenosyl-methionine (SAMe) versus oral imipramine in the treatment of depression. Presented at Collegium Internationale Neuro-Psychopharmacologisum (CINP); July 9-13, 2000; Brussels, Belgium.
70. Di Padova C, Giudici A, Boissard G. Ademetionine and depression. Presented at the V Workshop on "Methionine Metabolism: Molecular Mechanisms and Clinical Implications." February 20-24, 2000; Granada, Spain.
71. Torta R, Zanalda F, Rocca P, et al. Inhibitory activity of S-adenosyl-L-methionine on serum gamma-glutamyl-transpeptidase increase induced by psychodrugs and anticonvulsants. Current Therapeutic Research. 1988;44:144-159.
72. Agnoli A, Martucci N, Manna V. On the antidepressant effect of SAMe: clinical and pharmaco-EEG study with SAMe alone and in combination with a beta-2 stimulant drug, pheoterole. Clin Neuropharmacol. 1984;7(suppl 1):104-105.
73. Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAM and other antidepressant drugs. Cell Biology Review. 1987;S1:103-110.
74. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44:257-262.
75. Colell A, Garcia-Ruiz C, Morales A, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology. 1997;26:699-708.
76. Evans PJ, Whiteman M, Tredger JM, Halliwell B. Antioxidant properties of S-adenosyl-L-methionine: a proposed addition to organ storage fluids. Free Radic Biol Med. 1997;23:1002-1008.
77. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998;157(suppl 2):S40-S44.
78. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem. 1996;67:1328-1331.
79. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs. 1994;48:137-152.
80. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl. 1994;54:19-26.
81. Agnoli A, Andreoli VM, Cassachia M, Maffei F, Fazio C. Results and possible developments of the clinical use of S-Adenosyl-L-methionine (SAMe) in psychiatry. Monographien aus dem Gesamtgebiete der Psychiatrie. 1978;18:170-182.
82. Carney MW, Martin R, Bottiglieri T, et al. Switch mechanism in affective illness and S-Adenosylmethionine. Lancet. 1983;1:820-821.
83. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-Adenosylmethionine for treatment of depression. Am J Psychiatry. 1984;141:448-450.
84. Carney MW, Chari TK, Bottiglieri T, Reynolds EH, Toone BK. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry. 1987;150:724-725.
85. Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis: report of an open phase IV study with ademetionine (Gumbaral). Am J Med. 1987;83:84-88.
86. Turyn D, Scacchi GE, Dellacha JM. Unmasking of insulin receptors in rat submaxillary gland microsomes: effect of high ionic strength, phospholipase C and S-adenosyl-L-methionine. Biochim Biophys Acta. 1985;845:333-342.
87. Kowluru A, Seavey SE, Rabaglia ME, Nesher R, Metz SA. Carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting cells: evidence for functional consequences on enzyme activity and insulin secretion. Endocrinology. 1996;137:2315-2323.
88. Kowluru A, Rana RS, MacDonald MJ. Phospholipid methyltransferase activity in pancreatic islets: activation by calcium. Arch Biochem Biophys. 1985;242:72-81.
89. Otero-Losada ME, Rubio MC. Acute effects of S-adenosyl-L-methionine on catecholaminergic central function. Eur J Pharmacol. 1989;163:353-356.
90. Iruela LM, Minguez L, Merino J, et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150:522.
91. De la Cruz JP, Merida M, Gonzalez-Correa JA, Ortiz P, Sanchez de la Cuesta F. Effects of S-adenosylmethionine on blood platelet activation. Gen Pharmacol. 1997;29:651-655.
92. Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: results of a controlled clinical trial. Hepatogastroenterology. 1990;37(suppl 2):122-125.
93. Pezzoli C, Galli-Kienle M, Stramentinoli G. Lack of mutagenic activity of ademetionine in vitro and in vivo. Arzneimittelforschung. 1987;37:826-829.
94. Cozens DD, Barton SJ, Clark R, et al. Reproductive toxicity studies of ademetionine. Arzneimittelforschung. 1988;38:1625-1629.
95. Surtees R, Hyland K. A method for the measurement of S- adenosylmethionine in small volume samples of cerebrospinal fluid or brain using high-performance liquid chromatography-electrochemistry. Anal Biochem. 1989;181:331-335.
96. Faloon W. Counterfeit supplements. Life Extension. September 1999:7-9.
97. ConsumerLab.com. Independent Tests of Herbal, Vitamin, and Mineral Supplements: Product Review. SAMe. Available at www.ConsumerLab.com. Accessed November 8, 2000.
98. Consumer Reports. Emotional 'aspirin'? We tested what's in the alternative 'mood' pills. Consumer Reports. 2000;60-62.
99. Bell KM, Potkin SG, Carreon, D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl. 1994;154:15-18.
100. Brown R, Bottiglieri T, Colman C. Stop Depression Now. New York: Penguin Putnam; 1999.